arrow
S

Sayantani Sindher

Stanford University
H指数:32
被引数:4,215

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Corrigendum to ‘Skin as the target for allergy prevention and treatment’ [Annals of Allergy, Asthma & Immunology, Volume 133, Issue 2 (2024) 133–143]

勘误:‘Skin as the target for allergy prevention and treatment’ [Allergy, Asthma & Immunology学报,第133卷,第2期(2024年)133–143页]

2026-03-300
OAAI
Correspondence: First Peanut (Arachis hypogaea) Allergen Oral Immunotherapy Product Out of Sale—A Major Drawback for Food Allergy Immunotherapy?

通讯:首个花生(Arachis hypogaea)过敏原口服免疫疗法产品退出销售——这对食物过敏免疫疗法是一个重大挫折?

2026-02-120
PRE
Optimized Cellular Deconvolution of Skin Tape RNA-seq Reveals Cell Remodeling in Infant Atopic Dermatitis

优化后的皮肤贴带RNA-seq细胞解卷积揭示了婴儿特应性皮炎中的细胞重塑

2026-02-100
PRE
Management of gastrointestinal symptoms during oral immunotherapy: Guidance from OUtMATCH Investigators
2026-02-040
PREAI
A phase 2 randomized controlled trial using biologics to improve multi OIT outcomes (COMBINE): design; rationale; and methods

一项使用生物制剂改善多OIT结局的2期随机对照试验(COMBINE):设计;理由;和方法

2025-12-180
OAAI
Exploratory Analyses of Predictors and Correlates of Response to Omalizumab Therapy in Patients with Multiple Food Allergies

对多食物过敏患者奥马珠单抗治疗反应的预测因子和相关因素的探索性分析

2025-11-120
OAAI
Trends in allergen-reactive CRTH2+ T cells and TARC associated with successful outcomes in a phase 2 cashew oral immunotherapy study

与一个2期腰果口服免疫疗法研究成功结局相关的过敏原反应性CRTH2+ T细胞和TARC的趋势

2025-10-220
OAAI
Shrimp oral immunotherapy outcomes in the phase 2 clinical trial: MOTIF

虾口服免疫疗法在2期临床试验中的结果:MOTIF

2025-07-220
OA
Introduction of allergenic foods after treatment with omalizumab

奥马珠单抗治疗后致敏性食物的引入

2025-05-280
PRE
Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy

Dupilumab作为花生过敏患儿口服免疫治疗的辅助手段

2024-12-140
PRE
Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open-Label, Phase II Study
2024-12-140
OAAI